Test Price
2,500 AED✅ Home Collection Available
Minimal Residual Disease (MRD) Analysis for T-ALL in UAE | 2500 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This test uses multiparametric flow cytometry to detect residual leukemic cells at a sensitivity of 0.01%, guiding treatment de-escalation or intensification. The bone marrow aspirate is analyzed using the EuroFlow protocol with a comprehensive panel of fluorescent antibodies targeting T-cell lineage markers and aberrant antigen expression patterns, compared against the patient's original diagnostic immunophenotype.
| Feature | Our MRD Analysis (Flow Cytometry) | Standard MRD Testing |
|---|---|---|
| Method | Multiparametric Flow Cytometry (EuroFlow Protocol) | Basic Flow Cytometry (Limited Markers) |
| Sensitivity | 10⁻⁴ (0.01%) – High Diagnostic Precision | 10⁻³ (0.1%) or worse |
| Turnaround Time | 3 Working Days | 5–7 Working Days |
| Accreditation | ISO 9001:2015, DHA Licensed | May not be accredited |
| Collection Setting | Hospital Extraction Only | Often requires hospital visit |
Physician Insight & Safety Protocols
“Minimal residual disease analysis by flow cytometry provides an exquisitely sensitive window into the molecular behavior of T-ALL after induction therapy. A negative result (below 0.01%) offers reassurance of deep remission, while any detectable disease burden above this threshold signals the need for treatment intensification. I recommend correlating MRD findings with cytogenetic risk stratification and clinical response. Do not alter your treatment regimen based solely on an MRD report without consulting your hematologist.” — Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
⚠️ Critical Reminder: Medication Adherence
Never discontinue, reduce, or modify any prescribed chemotherapy, targeted therapy, or supportive medication without explicit authorization from your treating oncologist. Abrupt changes may compromise treatment efficacy and increase relapse risk.
Safety Exclusion Criteria & Red Flags
- Active systemic infection or sepsis (risk of dissemination during bone marrow sampling).
- Severe coagulopathy (INR greater than 2.0, platelet count below 20,000/µL) unless corrected prior to aspiration.
- Inability to provide mandatory pre-test information: date and time of sampling, prior immunophenotype report, and complete clinical history.
- Emergency Red Flags Post-Procedure: Intense local pain, bleeding that does not stop with pressure, fever exceeding 38°C, or any signs of infection at the puncture site. Seek immediate medical attention.
Patient FAQ & Clinical Guidance
1. What does a minimal residual disease (MRD) test for T-ALL measure?
Snippet Killer Answer: MRD analysis detects and quantifies extremely low levels of leukemic cells that remain after chemotherapy, using advanced flow cytometry with 0.01% sensitivity to guide treatment decisions and predict relapse risk.
Your hematologist may order this at specific treatment milestones to determine if you are in deep molecular remission or need additional therapy. The bone marrow sample is stained with a panel of fluorescent antibodies targeting T-cell markers and abnormal antigen expression patterns, then compared to the original diagnostic immunophenotype. Results are reported as a percentage of total nucleated cells.
2. How should I prepare for the bone marrow aspiration for MRD testing?
Snippet Killer Answer: No fasting is required; however, you must share your complete clinical history, previous immunophenotype report, and current medication list, and arrange for the sample to be drawn and shipped immediately at room temperature.
The procedure is typically performed from the posterior iliac crest under local anesthesia and takes about 15 minutes. The aspiration is conducted exclusively within an accredited hospital setting by a qualified physician. Both bone marrow aspirate (first pull) and a peripheral blood sample are collected in separate Sodium Heparin tubes, following strict DHA protocols. You will need to rest for a short period under observation after the procedure.
3. What do the results of MRD analysis mean for my T-ALL treatment?
Snippet Killer Answer: A negative MRD result (below 0.01%) suggests a favorable response, potentially allowing treatment reduction; a positive result indicates persistent leukemia, prompting therapy intensification or transplant consideration based on current clinical guidelines.
Your oncologist will interpret the values alongside clinical factors such as age, genetic mutations, and response to previous cycles. MRD levels are reported as a percentage of total nucleated cells; even a small positive result can have significant prognostic implications. Our telephonic clinical guidance can help you understand the report before your doctor's appointment, but final treatment decisions must be made by your treating consultant.
UAE Regulatory & Data Privacy Adherence
Healthcare Compliance Framework: This MRD analysis service operates in full compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability, Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL). All processing is conducted under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) and DHA facility license 1143. Your medical data is encrypted in transit and at rest, accessed only by authorized clinical personnel, and never disclosed without your explicit written consent.
Clinical & Logistical Metadata
| Test Name | Minimal Residual Disease (MRD) Analysis for T-ALL – Flow Cytometry |
| Price (AED) | 2,500 AED |
| Turnaround Time | 3 Working Days |
| Sample Type / Matrix | Bone Marrow Aspirate (first pull) and Peripheral Blood – Sodium Heparin Tubes; Hospital Extraction Only |
| Methodology Used | Multiparametric Flow Cytometry (EuroFlow Protocol), 8–10 Color Panel, Sensitivity 10⁻⁴ |
| ICD-10-CM Code | C91.00 (Acute lymphoblastic leukemia not having achieved remission), C91.02 (T-cell acute lymphoblastic leukemia) |
| LOINC Code | 100368-6 (Minimal residual disease [Presence] in Bone marrow by Flow cytometry) |
| DHA Facility License & Laboratory Address | DNA Labs UAE | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians